Asthma - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035

Asthma Market Outlook

Thelansis's "Asthma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Asthma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Asthma: Overview

Asthma is a chronic, heterogeneous inflammatory disorder of the airways characterized by recurrent wheezing, breathlessness, chest tightness, and cough, driven by airway hyperresponsiveness and variable, often reversible airflow obstruction. The underlying pathophysiology involves chronic airway inflammation, bronchoconstriction, mucus hypersecretion, and airway remodeling, contributing to disease persistence and severity in a subset of patients.

Diagnosis is based on clinical history and objective lung function testing, including spirometry with bronchodilator reversibility, while bronchial provocation tests are used in ambiguous cases. Disease control is assessed through symptom burden, exacerbation frequency, and lung function metrics.

Management follows a stepwise, treat-to-control approach, with inhaled corticosteroids (ICS) forming the cornerstone of maintenance therapy, often combined with long-acting beta-agonists (LABAs). Short-acting beta-agonists (SABAs) are used for rapid symptom relief. In moderate-to-severe or uncontrolled asthma, advanced therapies including biologics targeting IgE, IL-5, and IL-4/13 pathways are increasingly utilized.

Asthma is clinically heterogeneous, encompassing allergic, non-allergic, occupational, and exercise-induced phenotypes, requiring personalized treatment strategies. While prognosis is generally favorable with appropriate therapy, under-diagnosis, poor adherence, and limited access to inhaled therapies continue to drive preventable exacerbations and mortality globally.

Key Highlights

• In France, drug-treated asthma cases are projected to increase from 4,385,128 to 4,701,939, indicating steady growth in treated population.
• Diagnosis rate stands at 75.0%, highlighting a gap in identified patient population.
• Disease distribution shows 58% intermittent/mild and 42% moderate-to-severe population, reflecting a significant segment requiring advanced therapy.
• Rising burden driven by environmental factors, urbanization, and improved detection rates.
• Increasing adoption of biologics in moderate-to-severe asthma is reshaping treatment landscape.

Market Overview

• The France asthma market is projected to grow from $1.1B to $1.7B, reflecting strong market expansion.
• Market growth is driven by:
• Increased uptake of combination inhalers (ICS/LABA) and biologics
• Expansion of treated patient population
• Despite high prevalence, market value is supported by chronic therapy use and premium biologic adoption.
• Improved awareness and diagnosis are contributing to higher treatment penetration.
• Future growth will depend on biologic expansion, personalized therapy approaches, and improved adherence strategies.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Chiesi Farmaceutici S.p.A.
• Shanghai Mabgeek Biotech.Co.Ltd
• Apogee Therapeutics, Inc.
• GlaxoSmithKline
• AstraZeneca
• Trio Medicines Ltd.
• Amgen
• Arrowhead Pharmaceuticals
• Guangdong Hengrui Pharmaceutical Co., Ltd
• Innovent Biologics (Suzhou) Co. Ltd.
• Akeso
• Keymed Biosciences Co.Ltd
• Qilu Pharmaceutical Co., Ltd.
• Sanofi
• Novartis Pharmaceuticals
• Eli Lilly and Company
• Upstream Bio Inc.
• Regeneron Pharmaceuticals
• Equillium
• Pfizer
• Beijing Kanova Biopharmaceutical Co., LTD
• Generate Biomedicines
• SinoMab BioScience Ltd